JP2023544201A5 - - Google Patents

Info

Publication number
JP2023544201A5
JP2023544201A5 JP2023521092A JP2023521092A JP2023544201A5 JP 2023544201 A5 JP2023544201 A5 JP 2023544201A5 JP 2023521092 A JP2023521092 A JP 2023521092A JP 2023521092 A JP2023521092 A JP 2023521092A JP 2023544201 A5 JP2023544201 A5 JP 2023544201A5
Authority
JP
Japan
Prior art keywords
kit
composition
parts according
immune checkpoint
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023521092A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023544201A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/077777 external-priority patent/WO2022074152A1/en
Publication of JP2023544201A publication Critical patent/JP2023544201A/ja
Publication of JP2023544201A5 publication Critical patent/JP2023544201A5/ja
Pending legal-status Critical Current

Links

JP2023521092A 2020-10-08 2021-10-07 がんを処置するための免疫療法 Pending JP2023544201A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20200835.5 2020-10-08
EP20200835 2020-10-08
PCT/EP2021/077777 WO2022074152A1 (en) 2020-10-08 2021-10-07 Immunotherapy for the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2023544201A JP2023544201A (ja) 2023-10-20
JP2023544201A5 true JP2023544201A5 (https=) 2024-09-13

Family

ID=72811720

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023521092A Pending JP2023544201A (ja) 2020-10-08 2021-10-07 がんを処置するための免疫療法

Country Status (10)

Country Link
US (1) US20230372384A1 (https=)
EP (1) EP4225374A1 (https=)
JP (1) JP2023544201A (https=)
KR (1) KR20230084476A (https=)
CN (1) CN116348142A (https=)
AU (1) AU2021357354A1 (https=)
CA (1) CA3192963A1 (https=)
IL (1) IL301906A (https=)
MX (1) MX2023004101A (https=)
WO (1) WO2022074152A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL320615A (en) * 2022-11-07 2025-07-01 Targimmune Therapeutics Ag PSMA-targeting linear conjugates containing polyethyleneimine and polyethylene glycol and polyplexes containing the same materials
IL320618A (en) * 2022-11-07 2025-07-01 Targimmune Therapeutics Ag Polyplexes of nucleic acids and targeted pairs containing polyethyleneimine and polyethylene glycol
US20260000700A1 (en) * 2022-11-07 2026-01-01 Targimmune Therapeutics Ag Targeted linear conjugates comprising polyethyleneimine and polyethylene glycol and polyplexes comprising the same

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162504A (en) 1988-06-03 1992-11-10 Cytogen Corporation Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
US6368598B1 (en) 1996-09-16 2002-04-09 Jcrt Radiation Oncology Support Services, Inc. Drug complex for treatment of metastatic prostate cancer
US7205437B2 (en) 1996-11-27 2007-04-17 University Of Tennessee Research Foundation Selective androgen receptor modulators
US7759520B2 (en) 1996-11-27 2010-07-20 University Of Tennessee Research Foundation Synthesis of selective androgen receptor modulators
US7518013B2 (en) 2000-08-24 2009-04-14 University Of Tennessee Research Foundation Selective androgen receptor modulators
US6995284B2 (en) 2000-08-24 2006-02-07 The University Of Tennessee Research Foundation Synthesis of selective androgen receptor modulators
US20020173495A1 (en) 2000-08-24 2002-11-21 Dalton James T. Selective androgen receptor modulators and methods of use thereof
US20040260108A1 (en) 2001-06-25 2004-12-23 Dalton James T. Metabolites of selective androgen receptor modulators and methods of use thereof
DE60137728D1 (de) 2000-08-24 2009-04-02 Univ Tennessee Res Foundation Selektive Modulatoren des Androgenrezeptors und Methoden zu deren Verwendung
US7026500B2 (en) 2000-08-24 2006-04-11 University Of Tennessee Research Foundation Halogenated selective androgen receptor modulators and methods of use thereof
US6838484B2 (en) 2000-08-24 2005-01-04 University Of Tennessee Research Foundation Formulations comprising selective androgen receptor modulators
US20030232792A1 (en) 2000-08-24 2003-12-18 Dalton James T. Selective androgen receptor modulators and methods of use thereof
US6998500B2 (en) 2000-08-24 2006-02-14 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
IL154425A0 (en) 2000-08-24 2003-09-17 Univ Tennessee Res H Corp Selective androgen receptor modulators and methods of use thereof
US20030022868A1 (en) 2001-06-25 2003-01-30 Dalton James T. Selective androgen receptor modulators and methods of use thereof
US20060004042A1 (en) 2001-08-23 2006-01-05 Dalton James T Formulations comprising selective androgen receptor modulators
KR20030043780A (ko) 2001-11-28 2003-06-02 주식회사 바이오폴리메드 생체적합성 비항원성 공중합체와 그 결합체 및 이들의제조방법
AU2002357003A1 (en) 2001-12-28 2003-07-24 Guilford Pharmaceuticals Inc. Indoles as naaladase inhibitors
US20030232013A1 (en) 2002-02-22 2003-12-18 Gary Sieckman Therapeutic and diagnostic targeting of cancers cells with tumor homing peptides
AU2003217304A1 (en) 2002-02-28 2003-09-16 The University Of Tennessee Research Corporation Radiolabeled selective androgen receptor modulators and their use in prostate cancer imaging and therapy
US7803970B2 (en) 2002-02-28 2010-09-28 University Of Tennessee Research Foundation Multi-substitued selective androgen receptor modulators and methods of use thereof
US7705182B2 (en) 2002-02-28 2010-04-27 University Of Tennessee Research Foundation Multi-substituted selective androgen receptor modulators and methods of use thereof
HRP20040818A2 (en) 2002-02-28 2005-02-28 University Of Tennessee Research Foundation Haloacetamide and azide substituted compounds and methods of use thereof
JP2005529952A (ja) 2002-06-17 2005-10-06 ユニバーシティ・オブ・テネシー・リサーチ・ファウンデーション Ｎ架橋選択的アンドロゲン受容体修飾物質及びその使用方法
US7741371B2 (en) 2002-06-17 2010-06-22 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
CA2502209A1 (en) 2002-10-15 2004-04-29 University Of Tennessee Research Foundation Methylene-bridged selective androgen receptor modulators and methods of use thereof
US20040087810A1 (en) 2002-10-23 2004-05-06 Dalton James T. Irreversible selective androgen receptor modulators and methods of use thereof
JP4603528B2 (ja) 2003-01-13 2010-12-22 ジーティーエックス・インコーポレイテッド 選択的アンドロゲン受容体の大規模合成
US20040167103A1 (en) 2003-02-24 2004-08-26 Dalton James T. Haloacetamide and azide substituted compounds and methods of use thereof
US20060258628A1 (en) 2004-07-20 2006-11-16 Steiner Mitchell S Compositions comprising 5-alpha reductase inhibitors, and SARMs and methods of use thereof
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
US20070225213A1 (en) 2006-03-23 2007-09-27 Kosak Matthew K Nucleic acid carriers for delivery of therapeutic agents
CA2648099C (en) 2006-03-31 2012-05-29 The Brigham And Women's Hospital, Inc System for targeted delivery of therapeutic agents
WO2008124634A1 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Polymer-encapsulated reverse micelles
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
PL2187965T3 (pl) 2007-08-17 2020-05-18 Purdue Research Foundation Koniugaty wiążący psma ligand-łącznik i sposoby ich zastosowania
EP2436376B1 (en) 2007-09-28 2014-07-09 BIND Therapeutics, Inc. Cancer cell targeting using nanoparticles
WO2009131435A1 (en) 2008-04-23 2009-10-29 Erasmus University Medical Center Rotterdam Linker containing bungarotoxin and a binding peptide
JP2011525180A (ja) 2008-06-16 2011-09-15 バインド バイオサイエンシズ インコーポレイテッド 治療的標的化ナノ粒子の製作に用いるためのジブロックコポリマーで官能化された標的薬の製造方法
WO2010045598A2 (en) 2008-10-17 2010-04-22 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
US8287910B2 (en) 2009-04-30 2012-10-16 Intezyne Technologies, Inc. Polymeric micelles for polynucleotide encapsulation
PL2504364T3 (pl) 2009-11-24 2017-12-29 Medimmune Limited Ukierunkowane środki wiążące przeciwko B7-H1
EP2515942B1 (en) 2009-12-15 2020-02-12 Pfizer Inc. Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers
EA201290497A1 (ru) 2009-12-15 2013-01-30 Байнд Байосайенсиз, Инк. Терапевтические полимерные наночастицы, включающие кортикостероиды, и способы получения таковых
WO2011084521A2 (en) 2009-12-15 2011-07-14 Bind Biosciences, Inc. Therapeutic polymeric nanoparticles comprising epothilone and methods of making and using same
EP2542678B1 (en) 2010-03-04 2017-04-12 InteRNA Technologies B.V. A MiRNA MOLECULE DEFINED BY ITS SOURCE AND ITS THERAPEUTIC USES IN CANCER ASSOCIATED WITH EMT
EP2591106A1 (en) 2010-07-06 2013-05-15 InteRNA Technologies B.V. Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
WO2012016188A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
EP2691120A4 (en) 2011-03-31 2014-09-24 Univ Johns Hopkins THEROSTATIC ILLUSTRATION AND USE METHOD THEREFOR
US20140308363A1 (en) 2011-05-31 2014-10-16 Bind Therapeutics, Inc. Drug loaded polymeric nanoparticles and methods of making and using same
EP2917348A1 (en) 2012-11-06 2015-09-16 InteRNA Technologies B.V. Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated b-raf pathway
PE20170312A1 (es) 2014-03-14 2017-03-30 Pfizer Nanoparticulas terapeuticas que comprenden un agente terapeutico, y metodos para su elaboracion y uso
EP3137105A4 (en) 2014-04-30 2017-12-27 President and Fellows of Harvard College Combination vaccine devices and methods of killing cancer cells
KR102589295B1 (ko) * 2014-05-14 2023-10-13 타르그이뮨 테라퓨틱스 아게 개선된 폴리에틸렌이민 폴리에틸렌글리콜 벡터
US20160331845A1 (en) 2015-05-14 2016-11-17 The Johns Hopkins University Compositions of nucleic acid-containing nanoparticles for in vivo delivery
US20170209374A1 (en) 2015-09-11 2017-07-27 Pfizer Inc. Methods of controlling the morphology of polymeric nanoparticles
DK3378482T5 (da) 2015-11-19 2024-09-30 Univ Nagoya City Public Univ Corp Formulering til administration af antitumorlægemiddel
JP2018535228A (ja) 2015-11-25 2018-11-29 ファイザー・インク 抗生物質を含む治療用ナノ粒子ならびにそれを作製および使用する方法
IL273195B2 (en) 2017-09-27 2024-04-01 Targimmune Therapeutics Ag Castration-resistant prostate cancer
WO2020077077A1 (en) * 2018-10-10 2020-04-16 The Regents Of The University Of California Combination immunotherapies
KR20210146952A (ko) * 2019-04-03 2021-12-06 타르그이뮨 테라퓨틱스 아게 암의 치료를 위한 면역요법

Similar Documents

Publication Publication Date Title
JP2023544201A5 (https=)
Salameh et al. Polymer‐mediated gene therapy: Recent advances and merging of delivery techniques
ES3038616T3 (en) Improved cell-targeting binding molecule
He et al. pH-sensitive drug-delivery systems for tumor targeting
RU2016146389A (ru) Улучшенные полиэтилениминовые полиэтиленгликолевые векторы
Cai et al. Effective gene delivery using stimulus-responsive catiomer designed with redox-sensitive disulfide and acid-labile imine linkers
York et al. Rational design of targeted cancer therapeutics through the multiconjugation of folate and cleavable siRNA to RAFT-synthesized (HPMA-s-APMA) copolymers
Wang et al. Nanoparticles functionalized with Pep-1 as potential glioma targeting delivery system via interleukin 13 receptor α2-mediated endocytosis
ES2661461T3 (es) Polímeros de polioxazolina y métodos para su preparación, conjugados de estos polímeros, y sus usos médicos
Kasala et al. Utilizing adenovirus vectors for gene delivery in cancer
Albertazzi et al. Enhanced bioactivity of internally functionalized cationic dendrimers with PEG cores
KR100953917B1 (ko) 항체의 Ｆｃ 영역에 특이적 결합능을 가지는 리포펩타이드 및 그를 포함하는 항원 인지형 지질 나노입자
Nuhn et al. New Perspectives of HPMA‐based Copolymers Derived by Post‐Polymerization Modification
FI3283521T3 (fi) Lääkekonjugaatteja käsittäen vasta-aineita claudiinia 18.2 vastaan
Pan et al. Monoclonal antibody 2C5-modified mixed dendrimer micelles for tumor-targeted codelivery of chemotherapeutics and siRNA
Jiang et al. Targeted delivery of CXCR4-siRNA by scFv for HER2+ breast cancer therapy
Liu et al. An oligopeptide ligand-mediated therapeutic gene nanocomplex for liver cancer-targeted therapy
JP2011511773A5 (https=)
Wang et al. A photoresponsive antibody–siRNA conjugate for activatable immunogene therapy of cancer
AR069903A1 (es) Conjugado anticuerpo- molecula asociada dirigidos a la proteina tirosina quinasa 7 (ptk 7), composicion farmaceutica que lo comprende, acido nucleico, factor de expresion y celula huesped relacionados y su uso para preparar un medicamento util para el tratamiento o prevencion de cancer
JP2011529492A5 (https=)
JP2014521661A5 (https=)
Song et al. Multifunctional disulfide-based cationic dextran conjugates for intravenous gene delivery targeting ovarian cancer cells
Li et al. Captopril-polyethyleneimine conjugate modified gold nanoparticles for co-delivery of drug and gene in anti-angiogenesis breast cancer therapy
Gunasekaran et al. Conjugation of siRNA with comb‐type PEG enhances serum stability and gene silencing efficiency